Editas Medicine (EDIT) Non-Current Deffered Revenue (2015 - 2025)
Editas Medicine (EDIT) posted quarterly Non-Current Deffered Revenue of $44.5 million for Q4 2025, down 17.89% year-over-year from $54.2 million in Q4 2024, and down 17.89% quarter-over-quarter from $54.2 million in Q3 2025.
Editas Medicine (EDIT) Non-Current Deffered Revenue (2015 - 2025) Analysis & Trends
Editas Medicine (EDIT) has reported Non-Current Deffered Revenue for 11 consecutive years, with $44.5 million the latest figure, recorded in Q4 2025.
- In Q4 2025, Non-Current Deffered Revenue fell 17.89% year-over-year to $44.5 million; the TTM figure through Dec 2025 stood at $44.5 million (down 17.89% YoY), while the FY2025 annual figure was $44.5 million, down 17.89% from the prior year.
- Non-Current Deffered Revenue retreated to $44.5 million in Q4 2025 per EDIT's latest filing, from $54.2 million in the prior quarter.
- Across five years, Non-Current Deffered Revenue topped out at $68.9 million in Q2 2022 and bottomed at $44.5 million in Q4 2025.
- Historically, Non-Current Deffered Revenue has averaged $57.8 million across 5 years, with a median of $58.7 million in 2021.
- Annual changes were most pronounced in 2021 — Non-Current Deffered Revenue tumbled 60.1% — and 2022, when it climbed 24.75%.
- Editas Medicine's Non-Current Deffered Revenue stood at $60.9 million in 2021, then retreated by 0.36% to $60.7 million in 2022, then changed by 0.0% to $60.7 million in 2023, then fell by 10.65% to $54.2 million in 2024, then declined by 17.89% to $44.5 million in 2025.
- Business Quant data shows EDIT's Non-Current Deffered Revenue at $44.5 million in Q4 2025, $54.2 million in Q3 2025, and $54.2 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Deffered Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 220.40 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | - |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | - |
| 10 | Editas Medicine | 263.01 Mn | 116.36 Mn | - | 44.51 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 44.51 Mn |
| Sep 30, 2025 | 54.20 Mn |
| Jun 30, 2025 | 54.20 Mn |
| Mar 31, 2025 | 54.20 Mn |
| Dec 31, 2024 | 54.20 Mn |
| Sep 30, 2024 | 54.20 Mn |
| Jun 30, 2024 | 54.20 Mn |
| Mar 31, 2024 | 54.20 Mn |
| Dec 31, 2023 | 60.67 Mn |
| Sep 30, 2023 | 60.67 Mn |
| Jun 30, 2023 | 60.67 Mn |
| Mar 31, 2023 | 60.67 Mn |
| Dec 31, 2022 | 60.67 Mn |
| Sep 30, 2022 | 64.67 Mn |
| Jun 30, 2022 | 68.89 Mn |
| Mar 31, 2022 | 60.89 Mn |
| Dec 31, 2021 | 60.89 Mn |
| Sep 30, 2021 | 60.89 Mn |
| Jun 30, 2021 | 55.22 Mn |
| Mar 31, 2021 | 56.67 Mn |